• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer to invest $200 million in Irish facility

Pfizer to invest $200 million in Irish facility

September 20, 2011
CenterWatch Staff

Pfizer has announced that it is to invest $200 million at its Grange Castle biotechnology manufacturing facility in Clondalkin, Co Dublin, according to PharmaTimes.

The investment will enable the drugs giant to introduce two new processing suites to the site and expand current production and product testing capabilities. Grange Castle is already one of the largest biotech manufacturing facilities in the world and currently produces two blockbusters - the pneumococcal disease vaccine Prevnar and the arthritis and psoriasis therapy Enbrel. The site currently employs 1,100 full-time staff.

Pfizer's chief financial officer, Frank D’Amelio, noted that with pharmaceutical and chemical products accounting for over 50% of Irish exports "and a long history in pharmaceutical excellence, Ireland is a prime location for this major investment.” He added that the Grange Castle project is "a strategic initiative that will allow us to further align and strengthen our manufacturing and supply network.”

The news was announced by Irish Taoiseach (prime minister) Enda Kenny, who noted that Pfizer has made "a tremendous contribution to Ireland’s life sciences industry since it first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment" to the country.

Pfizer has some 4,300 staff in Ireland across eight locations based in Cork, Dublin, Kildare and Limerick. Total investment by the company in the country exceeds $7 billion.

Upcoming Events

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing